Matches in Wikidata for { <http://www.wikidata.org/entity/Q99956466> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q99956466 description "clinical trial" @default.
- Q99956466 description "ensayo clínico" @default.
- Q99956466 description "ensayu clínicu" @default.
- Q99956466 description "klinisch onderzoek" @default.
- Q99956466 description "клінічне випробування" @default.
- Q99956466 description "临床试验" @default.
- Q99956466 name "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19" @default.
- Q99956466 name "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19" @default.
- Q99956466 type Item @default.
- Q99956466 label "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19" @default.
- Q99956466 label "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19" @default.
- Q99956466 prefLabel "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19" @default.
- Q99956466 prefLabel "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19" @default.
- Q99956466 P1132 Q99956466-39C84EFC-A8EA-4405-BC92-0928950C8F0C @default.
- Q99956466 P1476 Q99956466-9BD95919-A0BD-4330-BB03-AACAA8EF25BC @default.
- Q99956466 P17 Q99956466-CE88C923-9359-4610-9D53-393A188E7FF9 @default.
- Q99956466 P2899 Q99956466-1D6A822F-EAEC-49FA-9073-295C9B8D6393 @default.
- Q99956466 P3098 Q99956466-30BEA5E5-18E9-4341-853A-A89937AA451C @default.
- Q99956466 P31 Q99956466-5370ED53-58FE-4552-94F1-9744BDEF3EDD @default.
- Q99956466 P4135 Q99956466-C4832767-1F4F-42C2-BAC0-2B96A9FE3061 @default.
- Q99956466 P580 Q99956466-78C1BFAF-99E2-476D-ACCB-6DECD3C53E9D @default.
- Q99956466 P582 Q99956466-507A419D-DBE3-4890-8287-449D2E039BEB @default.
- Q99956466 P6099 Q99956466-E627780A-5B02-46A7-BC0B-BABD16BCC8EF @default.
- Q99956466 P8005 Q99956466-D760E7A9-BC88-44E2-BE0F-2BC4307C8AFE @default.
- Q99956466 P8363 Q99956466-D8E1D89E-607E-4802-9B78-441B4706B9B9 @default.
- Q99956466 P1132 "+940" @default.
- Q99956466 P1476 "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers" @default.
- Q99956466 P17 Q30 @default.
- Q99956466 P2899 "+18" @default.
- Q99956466 P3098 "NCT04519437" @default.
- Q99956466 P31 Q30612 @default.
- Q99956466 P4135 "+90" @default.
- Q99956466 P580 "2020-07-26T00:00:00Z" @default.
- Q99956466 P582 "2021-10-25T00:00:00Z" @default.
- Q99956466 P6099 Q5452194 @default.
- Q99956466 P8005 Q76649708 @default.
- Q99956466 P8363 Q78089383 @default.